Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Title: Once-weekly Oral Dosing of MK-8591 Protects Male Rhesus Macaques from Intrarectal SHIV109CP3 Challenge.

Markowitz M, Gettie A, St Bernard L, Andrews CD, Mohri H, Horowitz A, Grasperge BF, Blanchard JL, Niu T, Sun L, Fillgrove K, Hazuda DJ, Grobler JA.

J Infect Dis. 2019 Jun 7. pii: jiz271. doi: 10.1093/infdis/jiz271. [Epub ahead of print]

PMID:
31175822
2.

PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals.

Fromentin R, DaFonseca S, Costiniuk CT, El-Far M, Procopio FA, Hecht FM, Hoh R, Deeks SG, Hazuda DJ, Lewin SR, Routy JP, Sékaly RP, Chomont N.

Nat Commun. 2019 Feb 18;10(1):814. doi: 10.1038/s41467-019-08798-7.

3.

Active evolution of memory B-cells specific to viral gH/gL/pUL128/130/131 pentameric complex in healthy subjects with silent human cytomegalovirus infection.

Xia L, Tang A, Meng W, Freed DC, He L, Wang D, Li F, Li L, Xiong W, Gui X, Schultz RD, Chen H, He X, Swoyer R, Ha S, Liu Y, Morris CD, Zhou Y, Wang IM, Zhao Q, Luo W, Xia N, Espeseth AS, Hazuda DJ, Rupp RE, Barrett AD, Zhang N, Zhu J, Fu TM, An Z.

Oncotarget. 2017 Jun 3;8(43):73654-73669. doi: 10.18632/oncotarget.18359. eCollection 2017 Sep 26.

4.

Identification of novel bifunctional HIV-1 reverse transcriptase inhibitors.

Lai MT, Tawa P, Auger A, Wang D, Su HP, Yan Y, Hazuda DJ, Miller MD, Asante-Appiah E, Melnyk RA.

J Antimicrob Chemother. 2018 Jan 1;73(1):109-117. doi: 10.1093/jac/dkx332.

PMID:
29029095
5.

HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.

Wu G, Swanson M, Talla A, Graham D, Strizki J, Gorman D, Barnard RJ, Blair W, Søgaard OS, Tolstrup M, Østergaard L, Rasmussen TA, Sekaly RP, Archin NM, Margolis DM, Hazuda DJ, Howell BJ.

JCI Insight. 2017 Aug 17;2(16). pii: 92901. doi: 10.1172/jci.insight.92901. eCollection 2017 Aug 17.

6.

Discovery and optimization of 2-pyridinone aminal integrase strand transfer inhibitors for the treatment of HIV.

Schreier JD, Embrey MW, Raheem IT, Barbe G, Campeau LC, Dubost D, McCabe Dunn J, Grobler J, Hartingh TJ, Hazuda DJ, Klein D, Miller MD, Moore KP, Nguyen N, Pajkovic N, Powell DA, Rada V, Sanders JM, Sisko J, Steele TG, Wai J, Walji A, Xu M, Coleman PJ.

Bioorg Med Chem Lett. 2017 May 1;27(9):2038-2046. doi: 10.1016/j.bmcl.2017.02.039. Epub 2017 Feb 20.

PMID:
28285916
7.

Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions.

Lai MT, Munshi V, Lu M, Feng M, Hrin-Solt R, McKenna PM, Hazuda DJ, Miller MD.

Viruses. 2016 Sep 23;8(10). pii: E263. doi: 10.3390/v8100263.

8.

Latency reversal and viral clearance to cure HIV-1.

Margolis DM, Garcia JV, Hazuda DJ, Haynes BF.

Science. 2016 Jul 22;353(6297):aaf6517. doi: 10.1126/science.aaf6517. Review.

9.

In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.

Tsai P, Wu G, Baker CE, Thayer WO, Spagnuolo RA, Sanchez R, Barrett S, Howell B, Margolis D, Hazuda DJ, Archin NM, Garcia JV.

Retrovirology. 2016 May 21;13(1):36. doi: 10.1186/s12977-016-0268-7.

10.

A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.

Kovarova M, Swanson MD, Sanchez RI, Baker CE, Steve J, Spagnuolo RA, Howell BJ, Hazuda DJ, Garcia JV.

J Antimicrob Chemother. 2016 Jun;71(6):1586-96. doi: 10.1093/jac/dkw042. Epub 2016 Mar 21.

11.

Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.

Feng M, Sachs NA, Xu M, Grobler J, Blair W, Hazuda DJ, Miller MD, Lai MT.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2241-7. doi: 10.1128/AAC.02650-15. Print 2016 Apr.

12.

Correction to Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors.

Raheem IT, Walji AM, Klein D, Sanders JM, Powell DA, Abeywickrema P, Barbe G, Bennet A, Childers K, Christensen M, Clas SD, Dubost D, Embrey M, Grobler J, Hafey MJ, Hartingh TJ, Hazuda DJ, Kuethe JT, McCabe Dunn J, Miller MD, Moore KP, Nolting A, Pajkovic N, Patel S, Peng Z, Rada V, Rearden P, Schreier JD, Sisko J, Steele TG, Truchon JF, Wai J, Xu M, Coleman PJ.

J Med Chem. 2016 Jan 14;59(1):486. doi: 10.1021/acs.jmedchem.5b01957. Epub 2015 Dec 28. No abstract available.

PMID:
26709958
13.

A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals.

Procopio FA, Fromentin R, Kulpa DA, Brehm JH, Bebin AG, Strain MC, Richman DD, O'Doherty U, Palmer S, Hecht FM, Hoh R, Barnard RJ, Miller MD, Hazuda DJ, Deeks SG, Sékaly RP, Chomont N.

EBioMedicine. 2015 Jun 27;2(8):874-83. doi: 10.1016/j.ebiom.2015.06.019. eCollection 2015 Aug.

14.

Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors.

Raheem IT, Walji AM, Klein D, Sanders JM, Powell DA, Abeywickrema P, Barbe G, Bennet A, Childers K, Christensen M, Clas SD, Dubost D, Embrey M, Grobler J, Hafey MJ, Hartingh TJ, Hazuda DJ, Kuethe JT, McCabe Dunn J, Miller MD, Moore KP, Nolting A, Pajkovic N, Patel S, Peng Z, Rada V, Rearden P, Schreier JD, Sisko J, Steele TG, Truchon JF, Wai J, Xu M, Coleman PJ.

J Med Chem. 2015 Oct 22;58(20):8154-65. doi: 10.1021/acs.jmedchem.5b01037. Epub 2015 Oct 8. Erratum in: J Med Chem. 2016 Jan 14;59(1):486. Childers, Karla [added]; Christensen, Melodie [added]; Kuethe, Jeffrey T. [added]; McCabe Dunn, Jamie [added]; Nolting, Andrew [added]; Peng, Zuihui [corrected].

PMID:
26397965
15.

Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.

Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, Smith MZ, Spelman T, McMahon J, Velayudham P, Brown G, Roney J, Watson J, Prince MH, Hoy JF, Chomont N, Fromentin R, Procopio FA, Zeidan J, Palmer S, Odevall L, Johnstone RW, Martin BP, Sinclair E, Deeks SG, Hazuda DJ, Cameron PU, Sékaly RP, Lewin SR.

PLoS Pathog. 2014 Nov 13;10(10):e1004473. doi: 10.1371/journal.ppat.1004473. eCollection 2014 Oct.

16.

In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.

Feng M, Wang D, Grobler JA, Hazuda DJ, Miller MD, Lai MT.

Antimicrob Agents Chemother. 2015 Jan;59(1):590-8. doi: 10.1128/AAC.04201-14. Epub 2014 Nov 10.

17.

Derivatives of mesoxalic acid block translocation of HIV-1 reverse transcriptase.

Bernatchez JA, Paul R, Tchesnokov EP, Ngure M, Beilhartz GL, Berghuis AM, Lavoie R, Li L, Auger A, Melnyk RA, Grobler JA, Miller MD, Hazuda DJ, Hecht SM, Götte M.

J Biol Chem. 2015 Jan 16;290(3):1474-84. doi: 10.1074/jbc.M114.614305. Epub 2014 Oct 29.

18.

Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques.

Del Prete GQ, Shoemaker R, Oswald K, Lara A, Trubey CM, Fast R, Schneider DK, Kiser R, Coalter V, Wiles A, Wiles R, Freemire B, Keele BF, Estes JD, Quiñones OA, Smedley J, Macallister R, Sanchez RI, Wai JS, Tan CM, Alvord WG, Hazuda DJ, Piatak M Jr, Lifson JD.

Antimicrob Agents Chemother. 2014 Nov;58(11):6790-806. doi: 10.1128/AAC.03746-14. Epub 2014 Sep 2.

19.

Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences.

Grobler JA, Hazuda DJ.

Curr Opin Virol. 2014 Oct;8:98-103. doi: 10.1016/j.coviro.2014.07.006. Epub 2014 Aug 14. Review.

PMID:
25128610
20.

Effects of treatment with suppressive combination antiretroviral drug therapy and the histone deacetylase inhibitor suberoylanilide hydroxamic acid; (SAHA) on SIV-infected Chinese rhesus macaques.

Ling B, Piatak M Jr, Rogers L, Johnson AM, Russell-Lodrigue K, Hazuda DJ, Lifson JD, Veazey RS.

PLoS One. 2014 Jul 17;9(7):e102795. doi: 10.1371/journal.pone.0102795. eCollection 2014.

21.

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.

Archin NM, Bateson R, Tripathy MK, Crooks AM, Yang KH, Dahl NP, Kearney MF, Anderson EM, Coffin JM, Strain MC, Richman DD, Robertson KR, Kashuba AD, Bosch RJ, Hazuda DJ, Kuruc JD, Eron JJ, Margolis DM.

J Infect Dis. 2014 Sep 1;210(5):728-35. doi: 10.1093/infdis/jiu155. Epub 2014 Mar 11.

22.

In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

Lai MT, Feng M, Falgueyret JP, Tawa P, Witmer M, DiStefano D, Li Y, Burch J, Sachs N, Lu M, Cauchon E, Campeau LC, Grobler J, Yan Y, Ducharme Y, Côté B, Asante-Appiah E, Hazuda DJ, Miller MD.

Antimicrob Agents Chemother. 2014;58(3):1652-63. doi: 10.1128/AAC.02403-13. Epub 2013 Dec 30.

23.

Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies.

Barnard RJ, Howe JA, Ogert RA, Zeuzem S, Poordad F, Gordon SC, Ralston R, Tong X, Sniukiene V, Strizki J, Ryan D, Long J, Qiu P, Brass CA, Albrecht J, Burroughs M, Vuocolo S, Hazuda DJ.

Virology. 2013 Sep;444(1-2):329-36. doi: 10.1016/j.virol.2013.06.029. Epub 2013 Jul 19.

24.

Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection.

Hazuda DJ, Burroughs M, Howe AY, Wahl J, Venkatraman S.

Ann N Y Acad Sci. 2013 Jul;1291:69-76. doi: 10.1111/nyas.12218. Review.

PMID:
23859802
25.

Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis.

Barnard RJ, McHale CM, Newhard W, Cheney CA, Graham DJ, Himmelberger AL, Strizki J, Hwang PM, Rivera AA, Reeves JD, Nickle D, Dinubile MJ, Hazuda DJ, Mobashery N.

Virology. 2013 Sep 1;443(2):278-84. doi: 10.1016/j.virol.2013.05.013. Epub 2013 Jun 10.

26.

Combined approaches for HIV cure.

Margolis DM, Hazuda DJ.

Curr Opin HIV AIDS. 2013 May;8(3):230-5. doi: 10.1097/COH.0b013e32835ef089. Review.

27.

Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial.

Ogert RA, Howe JA, Vierling JM, Kwo PY, Lawitz EJ, McCone J, Schiff ER, Pound D, Davis MN, Gordon SC, Ravendhran N, Rossaro L, Jacobson IM, Ralston R, Chaudhri E, Qiu P, Pedicone LD, Brass CA, Albrecht JK, Barnard RJ, Hazuda DJ, Howe AY.

Antivir Ther. 2013;18(3):387-97. doi: 10.3851/IMP2549. Epub 2013 Feb 13.

PMID:
23406826
28.

Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques.

Klatt NR, Canary LA, Sun X, Vinton CL, Funderburg NT, Morcock DR, Quiñones M, Deming CB, Perkins M, Hazuda DJ, Miller MD, Lederman MM, Segre JA, Lifson JD, Haddad EK, Estes JD, Brenchley JM.

J Clin Invest. 2013 Feb;123(2):903-7. doi: 10.1172/JCI66227. Epub 2013 Jan 16.

29.

HIV integrase as a target for antiretroviral therapy.

Hazuda DJ.

Curr Opin HIV AIDS. 2012 Sep;7(5):383-9. doi: 10.1097/COH.0b013e3283567309. Review.

PMID:
22871634
30.

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.

Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM.

Nature. 2012 Jul 25;487(7408):482-5. doi: 10.1038/nature11286. Erratum in: Nature. 2012 Sep 20;489(7416):460.

31.

MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.

Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, Coleman PJ, Dimuzio JM, Ferrara M, Di Filippo M, Gates AT, Graham DJ, Harper S, Hazuda DJ, Huang Q, McHale C, Monteagudo E, Pucci V, Rowley M, Rudd MT, Soriano A, Stahlhut MW, Vacca JP, Olsen DB, Liverton NJ, Carroll SS.

Antimicrob Agents Chemother. 2012 Aug;56(8):4161-7. doi: 10.1128/AAC.00324-12. Epub 2012 May 21. Erratum in: Antimicrob Agents Chemother. 2014 Aug;58(8):4995. Huang, Qian [added].

32.

HIV-1 antiretroviral drug therapy.

Arts EJ, Hazuda DJ.

Cold Spring Harb Perspect Med. 2012 Apr;2(4):a007161. doi: 10.1101/cshperspect.a007161. Review.

33.

Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor.

Lu M, Felock PJ, Munshi V, Hrin RC, Wang YJ, Yan Y, Munshi S, McGaughey GB, Gomez R, Anthony NJ, Williams TM, Grobler JA, Hazuda DJ, McKenna PM, Miller MD, Lai MT.

Antimicrob Agents Chemother. 2012 Jun;56(6):3324-35. doi: 10.1128/AAC.00102-12. Epub 2012 Mar 5.

34.

Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system.

Brown AN, McSharry JJ, Adams JR, Kulawy R, Barnard RJ, Newhard W, Corbin A, Hazuda DJ, Louie A, Drusano GL.

Antimicrob Agents Chemother. 2012 Mar;56(3):1170-81. doi: 10.1128/AAC.05383-11. Epub 2011 Dec 12.

35.

Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.

Nguyen BY, Isaacs RD, Teppler H, Leavitt RY, Sklar P, Iwamoto M, Wenning LA, Miller MD, Chen J, Kemp R, Xu W, Fromtling RA, Vacca JP, Young SD, Rowley M, Lower MW, Gottesdiener KM, Hazuda DJ.

Ann N Y Acad Sci. 2011 Mar;1222:83-9. doi: 10.1111/j.1749-6632.2011.05972.x. Review.

PMID:
21434946
36.

Resistance to inhibitors of the human immunodeficiency virus type 1 integration.

Hazuda DJ.

Braz J Infect Dis. 2010 Sep-Oct;14(5):513-8. Review.

37.

Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment.

Liu J, Miller MD, Danovich RM, Vandergrift N, Cai F, Hicks CB, Hazuda DJ, Gao F.

Antimicrob Agents Chemother. 2011 Mar;55(3):1114-9. doi: 10.1128/AAC.01492-10. Epub 2010 Dec 20.

38.

Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold.

Williams PD, Staas DD, Venkatraman S, Loughran HM, Ruzek RD, Booth TM, Lyle TA, Wai JS, Vacca JP, Feuston BP, Ecto LT, Flynn JA, DiStefano DJ, Hazuda DJ, Bahnck CM, Himmelberger AL, Dornadula G, Hrin RC, Stillmock KA, Witmer MV, Miller MD, Grobler JA.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6754-7. doi: 10.1016/j.bmcl.2010.08.135. Epub 2010 Sep 24.

PMID:
20869872
39.

Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.

Lai MT, Lu M, Felock PJ, Hrin RC, Wang YJ, Yan Y, Munshi S, McGaughey GB, Tynebor RM, Tucker TJ, Williams TM, Grobler JA, Hazuda DJ, McKenna PM, Miller MD.

Antimicrob Agents Chemother. 2010 Nov;54(11):4812-24. doi: 10.1128/AAC.00829-10. Epub 2010 Aug 30.

40.

Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor.

Bar-Magen T, Sloan RD, Donahue DA, Kuhl BD, Zabeida A, Xu H, Oliveira M, Hazuda DJ, Wainberg MA.

J Virol. 2010 Sep;84(18):9210-6. doi: 10.1128/JVI.01164-10. Epub 2010 Jul 7.

41.

Triple Hyp→Pro replacement in integramide A, a peptaib inhibitor of HIV-1 integrase: Effect on conformation and bioactivity.

De Zotti M, De Borggraeve W, Kaptein B, Broxterman QB, Singh SB, Felock PJ, Hazuda DJ, Formaggio F, Toniolo C.

Biopolymers. 2011;96(1):49-59. doi: 10.1002/bip.21461.

PMID:
20560143
42.

Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors.

Su HP, Yan Y, Prasad GS, Smith RF, Daniels CL, Abeywickrema PD, Reid JC, Loughran HM, Kornienko M, Sharma S, Grobler JA, Xu B, Sardana V, Allison TJ, Williams PD, Darke PL, Hazuda DJ, Munshi S.

J Virol. 2010 Aug;84(15):7625-33. doi: 10.1128/JVI.00353-10. Epub 2010 May 19.

43.

SAR of tertiary carbinamine derived BACE1 inhibitors: role of aspartate ligand amine pKa in enzyme inhibition.

Rajapakse HA, Nantermet PG, Selnick HG, Barrow JC, McGaughey GB, Munshi S, Lindsley SR, Young MB, Ngo PL, Holloway MK, Lai MT, Espeseth AS, Shi XP, Colussi D, Pietrak B, Crouthamel MC, Tugusheva K, Huang Q, Xu M, Simon AJ, Kuo L, Hazuda DJ, Graham S, Vacca JP.

Bioorg Med Chem Lett. 2010 Mar 15;20(6):1885-9. doi: 10.1016/j.bmcl.2010.01.137. Epub 2010 Feb 4.

PMID:
20176482
44.

Assessment of the susceptibility of mutant HIV-1 to antiviral agents.

Wang YJ, McKenna PM, Hrin R, Felock P, Lu M, Jones KG, Coburn CA, Grobler JA, Hazuda DJ, Miller MD, Lai MT.

J Virol Methods. 2010 May;165(2):230-7. doi: 10.1016/j.jviromet.2010.02.002. Epub 2010 Feb 11.

PMID:
20153375
45.

Rapid P1 SAR of brain penetrant tertiary carbinamine derived BACE inhibitors.

Zhu H, Young MB, Nantermet PG, Graham SL, Colussi D, Lai MT, Pietrak B, Price EA, Sankaranarayanan S, Shi XP, Tugusheva K, Holahan MA, Michener MS, Cook JJ, Simon A, Hazuda DJ, Vacca JP, Rajapakse HA.

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1779-82. doi: 10.1016/j.bmcl.2010.01.005. Epub 2010 Jan 11.

PMID:
20122828
46.

Purification of untagged HIV-1 reverse transcriptase by affinity chromatography.

Lu M, Ngo W, Mei Y, Munshi V, Burlein C, Loughran MH, Williams PD, Hazuda DJ, Miller MD, Grobler JA, Diamond TL, Lai MT.

Protein Expr Purif. 2010 Jun;71(2):231-9. doi: 10.1016/j.pep.2010.01.001. Epub 2010 Jan 8.

PMID:
20060474
47.

Total synthesis, characterization, and conformational analysis of the naturally occurring hexadecapeptide integramide A and a diastereomer.

De Zotti M, Damato F, Formaggio F, Crisma M, Schievano E, Mammi S, Kaptein B, Broxterman QB, Felock PJ, Hazuda DJ, Singh SB, Kirschbaum J, Brückner H, Toniolo C.

Chemistry. 2010 Jan 4;16(1):316-27. doi: 10.1002/chem.200900945.

PMID:
19937615
48.

Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors.

Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, Margolis DM.

AIDS. 2009 Sep 10;23(14):1799-806. doi: 10.1097/QAD.0b013e32832ec1dc.

49.

Host cell factors in HIV replication: meta-analysis of genome-wide studies.

Bushman FD, Malani N, Fernandes J, D'Orso I, Cagney G, Diamond TL, Zhou H, Hazuda DJ, Espeseth AS, König R, Bandyopadhyay S, Ideker T, Goff SP, Krogan NJ, Frankel AD, Young JA, Chanda SK.

PLoS Pathog. 2009 May;5(5):e1000437. doi: 10.1371/journal.ppat.1000437. Epub 2009 May 29. Review.

50.

Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.

Lai MT, Munshi V, Touch S, Tynebor RM, Tucker TJ, McKenna PM, Williams TM, DiStefano DJ, Hazuda DJ, Miller MD.

Antimicrob Agents Chemother. 2009 Jun;53(6):2424-31. doi: 10.1128/AAC.01559-08. Epub 2009 Mar 16.

Supplemental Content

Loading ...
Support Center